In the past week, CABA stock has gone down by -14.46%, with a monthly decline of -22.81% and a quarterly plunge of -36.78%. The volatility ratio for the week is 6.97%, and the volatility levels for the last 30 days are 6.17% for Cabaletta Bio Inc The simple moving average for the last 20 days is -20.31% for CABA’s stock, with a simple moving average of -24.98% for the last 200 days.
Is It Worth Investing in Cabaletta Bio Inc (NASDAQ: CABA) Right Now?
The 36-month beta value for CABA is also noteworthy at 2.46. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CABA is 39.14M, and at present, short sellers hold a 21.72% of that float. The average trading volume of CABA on April 25, 2024 was 963.39K shares.
CABA) stock’s latest price update
The stock price of Cabaletta Bio Inc (NASDAQ: CABA) has dropped by -2.70 compared to previous close of 13.32. Despite this, the company has seen a fall of -14.46% in its stock price over the last five trading days. Seeking Alpha reported 2024-01-31 that Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with systemic lupus erythematosus [both renal and non-renal], is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with myositis, is expected in the 1st half of 2024. Initial data from the phase 1/2 study, using CABA-201 for the treatment of patients with generalized myasthenia gravis, is expected in the 2nd half of 2024.
Analysts’ Opinion of CABA
Many brokerage firms have already submitted their reports for CABA stocks, with Jefferies repeating the rating for CABA by listing it as a “Buy.” The predicted price for CABA in the upcoming period, according to Jefferies is $36 based on the research report published on February 05, 2024 of the current year 2024.
William Blair, on the other hand, stated in their research note that they expect to see CABA reach a price target of $38. The rating they have provided for CABA stocks is “Outperform” according to the report published on November 29th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to CABA, setting the target price at $40 in the report published on October 24th of the previous year.
CABA Trading at -33.00% from the 50-Day Moving Average
After a stumble in the market that brought CABA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.82% of loss for the given period.
Volatility was left at 6.17%, however, over the last 30 days, the volatility rate increased by 6.97%, as shares sank -23.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.16% lower at present.
During the last 5 trading sessions, CABA fell by -14.46%, which changed the moving average for the period of 200-days by unch in comparison to the 20-day moving average, which settled at $16.06. In addition, Cabaletta Bio Inc saw -42.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CABA starting from Binder Gwendolyn, who sale 11,000 shares at the price of $19.59 back on Jan 19 ’24. After this action, Binder Gwendolyn now owns 20,000 shares of Cabaletta Bio Inc, valued at $215,439 using the latest closing price.
Binder Gwendolyn, the of Cabaletta Bio Inc, sale 11,000 shares at $21.89 during a trade that took place back on Dec 19 ’23, which means that Binder Gwendolyn is holding 20,000 shares at $240,789 based on the most recent closing price.
Stock Fundamentals for CABA
The total capital return value is set at -0.31. Equity return is now at value -39.72, with -36.52 for asset returns.
Based on Cabaletta Bio Inc (CABA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -10.67. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 67.75.
Currently, EBITDA for the company is -73.23 million with net debt to EBITDA at 2.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.29.
Conclusion
In summary, Cabaletta Bio Inc (CABA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
